|
INPP5F expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.92279977998078E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.02159955442482E-10 |
| Normal-vs-Stage2 |
7.840300E-02 |
| Normal-vs-Stage3 |
4.39789999999718E-05 |
| Normal-vs-Stage4 |
6.45910000000027E-05 |
| Stage1-vs-Stage2 |
1.753020E-01 |
| Stage1-vs-Stage3 |
7.065800E-01 |
| Stage1-vs-Stage4 |
7.546200E-01 |
| Stage2-vs-Stage3 |
3.103000E-01 |
| Stage2-vs-Stage4 |
3.178600E-01 |
| Stage3-vs-Stage4 |
9.840200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
8.33039970338234E-10 |
| Normal-vs-AfricanAmerican |
3.000900E-03 |
| Normal-vs-Asian |
6.02800000026882E-07 |
| Caucasian-vs-AfricanAmerican |
9.769000E-01 |
| Caucasian-vs-Asian |
1.341420E-01 |
| AfricanAmerican-vs-Asian |
2.982200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.8060000000506E-06 |
| Normal-vs-Female |
6.07650041395402E-10 |
| Male-vs-Female |
6.670600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.7243998430323E-10 |
| Normal-vs-Age(41-60Yrs) |
1.39810000243656E-08 |
| Normal-vs-Age(61-80Yrs) |
9.020500E-03 |
| Normal-vs-Age(81-100Yrs) |
2.457800E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.113200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.884000E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.983200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.552200E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.342000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.721800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.925400E-01 |
| Classical-VS-Follicular |
4.12750000844397E-09 |
| Classical-VS-Other |
6.091200E-01 |
| Classical-VS-Normal |
1.73983050189008E-12 |
| Tall-VS-Follicular |
3.79839999997689E-06 |
| Tall-VS-Other |
6.321800E-01 |
| Tall-VS-Normal |
2.04960000083076E-08 |
| Follicular-VS-Other |
1.670630E-01 |
| Follicular-VS-Normal |
8.487200E-01 |
| Other-VS-Normal |
2.101800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.422070E-04 |
| Normal-vs-N1 |
1.536270E-03 |
| N0-vs-N1 |
7.266600E-01 |
|
|
